ABTEC.OL Aqua Bio Technology ASA
- Market cap
- NOK 72.8M
- P/E
- -
- P/B
- 1.66x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is ABTEC.OL undervalued?
Graham numberThe Graham number of Aqua Bio Technology ASA cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Aqua Bio Technology ASA fundamental analysis
No fundamental analysis for Aqua Bio Technology ASA yet.
Aqua Bio Technology ASA stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Aqua Bio Technology ASA
Aqua Bio Technology ASA, together with its subsidiary, develops and sells ingredients for skin care products in Norway. The company offers Aquabeautine XL, a proprietary ingredient for skincare products; and Spirulysat, an antioxidant and vitamin-boosted spirulina for cosmetic use. It also provides freight logistics solutions for trading companies. The company distributes its products through internet, stores, and skincare clinics. Aqua Bio Technology ASA was founded in 2000…
Full company profileAqua Bio Technology ASA financial statements
Aqua Bio Technology ASA annual financial statements (NOK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 0.00 | 1.21M | 878K | 891K | 444K | 1.56M | 7.02M | 18.4M | 107M | 1.34M |
| Gross Profit | 0.00 | -139K | -1.27M | -530K | -537K | 608K | 2.33M | 10.1M | 2.01M | 226K |
| Operating Income | 2.86M | -14.9M | -38.5M | -13.1M | -16.1M | -17.9M | -16.4M | -15.8M | -326M | -12.0M |
| EBITDA | - | - | - | - | - | - | -14.8M | -12.7M | 64.5M | -5.73M |
| Net Income | 1.46M | -16.1M | -38.5M | -13.2M | -14.7M | -19.1M | -18.7M | -21.0M | -337M | 97.7M |
| EPS | 0.21 | -2.32 | -5.55 | -0.86 | -0.80 | -0.93 | -45 | -22 | -155 | 32 |
| Balance Sheet | ||||||||||
| Total Assets | 71.4M | 49.1M | 9.94M | 10.4M | 16.2M | 34.4M | 67.2M | 238M | 250M | 130M |
| Total Liabilities | 9.65M | 10.6M | 10.1M | 3.06M | 7.92M | 15.7M | 65.3M | 152M | 331M | 131M |
| Shareholders' Equity | 61.8M | 38.5M | -197K | 7.32M | 8.32M | 18.7M | 1.86M | 85.8M | -81.7M | -489K |
| Cash & Short-term Investments | 43.3M | 20.5M | 3.27M | 6.88M | 5.43M | 13.4M | 1.86M | 5.02M | 17.2M | 2.43M |
| Cash Flow | ||||||||||
| Operating Cash Flow | 25.8M | -16.4M | -17.2M | -17.2M | -13.3M | -21.0M | -15.4M | -19.3M | -46.9M | -8.15M |
| Capital Expenditure | 408K | 936K | 358K | 17.8K | 136K | 3.87M | 0.00 | 1.41M | 1.08M | 0.00 |
| Free Cash Flow | - | - | - | - | - | -24.8M | -15.4M | -20.7M | -47.9M | -8.15M |
| Ratios | ||||||||||
| ROE | 2.4% | -41.7% | - | -180.5% | -176.7% | -102.2% | -1,007.0% | -24.5% | - | - |
| ROA | 2.0% | -32.7% | -387.2% | -127.2% | -90.6% | -55.5% | -27.9% | -8.8% | -135.1% | 75.1% |
| Net Profit Margin | - | -1,323.0% | -4,380.4% | -1,482.4% | -3,308.9% | -1,225.4% | -267.0% | -114.2% | -316.6% | 7,297.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Aqua Bio Technology ASA dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jun 8, 2017
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | NOK 6.22M | 0.90 | - |
| 2016 | NOK 16.9M | 2.44 | 1,157.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:50 on Feb 27, 2026.
Who owns Aqua Bio Technology ASA
- Insiders 32.74%
- Institutions 0.00%
- Public & others 67.27%
- Shares outstanding 15.5M
- Free float 4.34M
Aqua Bio Technology ASA company profile
- Company name
- Aqua Bio Technology ASA
- Ticker
- ABTEC.OL
- Exchange
- Oslo Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2
- Fiscal year end
- December
- Address
- Karenslyst Allé 10, Oslo, Norway, 0278
- Phone
- 47 95 09 23 22
- Website
- aquabiotechnology.com
About Aqua Bio Technology ASA
Aqua Bio Technology ASA, together with its subsidiary, develops and sells ingredients for skin care products in Norway. The company offers Aquabeautine XL, a proprietary ingredient for skincare products; and Spirulysat, an antioxidant and vitamin-boosted spirulina for cosmetic use. It also provides freight logistics solutions for trading companies. The company distributes its products through internet, stores, and skincare clinics. Aqua Bio Technology ASA was founded in 2000 and is headquartered in Oslo, Norway.
Aqua Bio Technology ASA management
3- Mr. Kristian FlatenCEO & CFO · born 1972
- Mr. Espen Østhagen KvaleChief Operating Officer · born 1976
- Mr. Hans Kristian LerenChief Technology Officer